Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Operating Expenses (2020 - 2025)

Bioventus' Operating Expenses history spans 6 years, with the latest figure at $85.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 4.8% year-over-year to $85.8 million; the TTM value through Dec 2025 reached $326.1 million, down 8.82%, while the annual FY2025 figure was $336.4 million, 8.64% down from the prior year.
  • Operating Expenses reached $85.8 million in Q4 2025 per BVS's latest filing, up from $81.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $100.9 million in Q2 2024 to a low of $35.6 million in Q2 2021.
  • Average Operating Expenses over 5 years is $82.0 million, with a median of $83.2 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 162.76% in 2022, then decreased 18.69% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $88.7 million in 2021, then fell by 0.76% to $88.0 million in 2022, then dropped by 7.33% to $81.5 million in 2023, then rose by 10.48% to $90.1 million in 2024, then dropped by 4.8% to $85.8 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Operating Expenses are $85.8 million (Q4 2025), $81.6 million (Q3 2025), and $82.3 million (Q2 2025).